Advesya aims to develop and commercialise CAR-T cell therapies focusing on haematology and oncology, targeting acute myeloid leukaemia (AML) based on a first-in-class approach with a high degree of tumour selectivity and an optimised safety profile. Their approach is based on an original target and a proprietary process, which makes advesya the company for the successful development of CAR-T cell therapy against AML.